Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
07 September 2023 - 6:00AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers for the treatment of
Alzheimer’s disease, announced today that management will present
at the H.C. Wainwright 25th Annual Global Investment Conference
on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET. The
live webcast may be accessed under the Investors tab
on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical
operations based in Carmel, IN, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are early and persistent triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AβOs, following
positive topline results in INTERCEPT-AD, a Phase 1 clinical trial
involving early Alzheimer’s disease patients. For more information,
visit www.acumenpharm.com.
Investors: Alex
Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2024 to May 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From May 2023 to May 2024